PRIME-ROSE – a European precision cancer medicine trial network and implementation initiative receives EUR 6 million from the EU Cancer Mission.
Precision cancer medicine uses genomics and other individual-level information for diagnostics and choice of treatment in cancer care.
The consortium will use existing adaptive and pragmatic clinical trial platforms to answer key questions regarding clinical effectiveness, provide health-economic evaluations, and contribute to scientific progress across cancers.
The PRIME-ROSE vision is access to affordable precision cancer medicine that prolongs life at the best quality possible for all cancer patients.
We are proud to contribute to PRIME-ROSE with the development of pragmatic strategies to take on key challenges for health economic evaluation of precision cancer medicine.